X4 Pharmaceuticals (XFOR) is said to have been approached by Italy’s Cheisi about a $1.86 per share offer, a source told Street Insider. X4 is ...

FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts.

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Licensing Agreement with Norgine Includes €28.5 Million Upfront Payment On January 13, 2025, X4 ...

U.S. economic growth slowed in the fourth quarter as a strike at Boeing depressed business investment in equipment, but ...

Gross domestic product grew by 2.3 percent in the fourth quarter, capping a more robust year than expected. Policy uncertainty clouds the outlook.

US economy grew at 2.3% rate in Q4 of 2024, slower than expected due to decline in investments. Tech companies' stocks mixed after earnings.

As of 11:44:29 AM EST. Market Open.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Since Moscow’s full-scale invasion of Ukraine in 2022, Russia’s economy has surpassed expectations. Its figures are, if not rosy, not ruinous either. Last year, the war economy likely grew ...

After the best two-year stretch for the S&P 500 (^GSPC) since the late 1990s, few on Wall Street are calling for an end to the bull market run, and this optimism serves as the key throughline in the ...

Federal economic data is one of the purest forms of infrastructure, says Erica Groshen, a former commissioner at the Bureau of Labor Statistics. “These data keep our economy running as much as ...